Literature DB >> 2245178

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.

B Desoize1, F Marechal, A Cattan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2245178      PMCID： PMC1971525          DOI： 10.1038/bjc.1990.390

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Superiority of perfusion over bolus administration in cancer chemotherapy: proposition of a compartmental model.

Authors:  B Desoize; E R Garrett
Journal:  Med Hypotheses       Date:  1989-05       Impact factor: 1.538

2.  Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

Authors:  M J Ratain; R L Schilsky; K E Choi; C Guarnieri; D Grimmer; N J Vogelzang; E Senekjian; M A Liebner
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Etoposide: a pharmacokinetic profile including an assessment of bioavailability.

Authors:  D Cunningham; L McTaggart; M Soukop; J Cummings; G J Forrest; J F Stuart
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

6.  Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

Authors:  J H Rodman; M Abromowitch; J A Sinkule; F A Hayes; G K Rivera; W E Evans
Journal:  J Clin Oncol       Date:  1987-07       Impact factor: 44.544

7.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

Authors:  J J Lokich; J D Ahlgren; J J Gullo; J A Philips; J G Fryer
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

Review 8.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

9.  Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

Authors:  M D'Incalci; C Rossi; M Zucchetti; R Urso; F Cavalli; C Mangioni; Y Willems; C Sessa
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701
  9 in total
  6 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 4.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 5.  Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.

Authors:  P Canal; E Gamelin; G Vassal; J Robert
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

6.  Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.

Authors:  John Carl Panetta; Mark Wilkinson; Ching-Hon Pui; Mary V Relling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.